<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029232</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-07-21</org_study_id>
    <nct_id>NCT05029232</nct_id>
  </id_info>
  <brief_title>Comprehensive Study of Duchenne Muscular Dystrophy at Sohag University Hospital</brief_title>
  <official_title>Comprehensive Study of Duchenne Muscular Dystrophy at Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscular dystrophies are a heterogenous group of inherited muscular disorders characterized&#xD;
      by progressive muscle weakness. Historically, these disorders are difficult to treat. In the&#xD;
      last three decades, there is a great progress in molecular and genetic basis of these&#xD;
      disorders; early diagnosis is achievable with proper clinical recognition and advanced&#xD;
      genetic testing .Duchenne Muscular Dystrophy (DMD) is a neuromuscular muscular X-linked&#xD;
      recessive disorders that belong to a group of disorders known as dystrophinopathies. DMD&#xD;
      characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest&#xD;
      early, at around 3 years, causing loss of ambulation within the 13 years of life, followed by&#xD;
      cardiac complication (e.g., dilated cardiomyopathy and arrhythmia) and respiratory disorders,&#xD;
      including chronic respiratory failure. The unique medical treatment available is steroid&#xD;
      therapy, which appears to prolong walking capacity by at least two years. Thus, besides&#xD;
      medical treatment, the physical therapy in multidisciplinary care is imperative for&#xD;
      alleviating muscle atrophy, skeletal deformities, and motor function deterioration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in dystrophine gene mutation</measure>
    <time_frame>within six months</time_frame>
    <description>MLPA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in MRI findings in DMX patient from normal</measure>
    <time_frame>within six months</time_frame>
    <description>by MRI brain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in cardiac function in DMD patient</measure>
    <time_frame>within six months</time_frame>
    <description>by Echocardiography to detect EF, FS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in thyroid function in DMD patient</measure>
    <time_frame>within six months</time_frame>
    <description>by thyroid function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in cognitive function in DMD patients</measure>
    <time_frame>within six months</time_frame>
    <description>by Stanford IQ test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>ambulant patient with DMD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient that walk alone or with minor assist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non ambulant patient with DMD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient need wheel chair</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MLPA for duchenne</intervention_name>
    <description>MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up</description>
    <arm_group_label>ambulant patient with DMD</arm_group_label>
    <arm_group_label>non ambulant patient with DMD</arm_group_label>
    <other_name>muscle enzymes</other_name>
    <other_name>thyroid function</other_name>
    <other_name>EMG , nerve conduction for limbs</other_name>
    <other_name>echocardiography , MRI brain , IQ test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age of onset between 3- and 18-year-old&#xD;
&#xD;
          2. typical clinical manifestation of Duchenne muscular dystrophy&#xD;
&#xD;
          3. clinical manifestation confirmed by specific biochemical analysis or by genetic&#xD;
             testing who presented to pediatric department and neurology outpatient clinic during&#xD;
             the period of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. children with another congenital muscular dystrophy&#xD;
&#xD;
          2. children with other types of myopathies&#xD;
&#xD;
          3. presence of CNS disorders such as brain insult &amp; spinal muscular atrophy&#xD;
&#xD;
          4. female gender&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>nehal s abdel magoud, assistant lecturer</last_name>
    <phone>01091666230</phone>
    <email>nehal.abdelmawgoud@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>abdel rahim A sadek, professor</last_name>
    <phone>01065067057</phone>
    <email>abdelreheam_sadek@med.sohag.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Osama R ElSherif, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Review. Erratum in: Lancet Neurol. 2018 Apr 4;:.</citation>
    <PMID>29395989</PMID>
  </reference>
  <reference>
    <citation>Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. Review.</citation>
    <PMID>29395990</PMID>
  </reference>
  <reference>
    <citation>Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic female carriers of Duchenne muscular dystrophy (DMD): genetic and clinical characterization. J Neurol Sci. 2014 Jan 15;336(1-2):36-41. doi: 10.1016/j.jns.2013.09.036. Epub 2013 Oct 5.</citation>
    <PMID>24135430</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Nehal Samy Abdo</investigator_full_name>
    <investigator_title>Assistant lecturer of pediatric. sohag university hospitals</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

